Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006)

Diagnostic Microbiology and Infectious Disease

Volumn 59, Issue 4, 2007, Pages 425-432

  Rhomberg, Paul R ^a   Deshpande, Lalitagauri M ^a   Kirby, Jeffrey T ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clonality; Meropenem; MYSTIC Program; Resistance; Serine carbapenemases; Surveillance

Indexed keywords

BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE CARBAPENEMASE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONING; DILUTION; DRUG POTENCY; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HEALTH PROGRAM; KLEBSIELLA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; THIENAMYCINS; UNITED STATES;

EID: 36549012175     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.05.009     Document Type: Article

References (42)

1. Alba J., Ishii Y., Thomson K., Moland E.S., and Yamaguchi K. Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing β-lactamase. Antimicrob. Agents Chemother. 49 (2005) 4760-4762
2. Arakawa Y., Shibata N., Shibayama K., Kurokawa H., Yagi T., Fujiwara H., and Goto M. Convenient test for screening metallo-β-lactamase-producing gram-negative bacteria by using thiol compounds. J. Clin. Microbiol. 38 (2000) 40-43
3. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50 (2004) 59-69
4. Bradford P.A., Bratu S., Urban C., Visalli M., Mariano N., Landman D., Rahal J.J., Brooks S., Cebular S., and Quale J. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39 (2004) 55-60
5. Bratu S., Landman D., Alam M., Tolentino E., and Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. 49 (2005) 776-778
6. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., and Quale J. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165 (2005) 1430-1435
7. Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., and Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56 (2005) 128-132
8. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 7th ed. (2006), CLSI, Wayne, PA M7-A7
9. Clinical and Laboratories Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard. 7th ed. (2007), CLSI, Wayne, PA M11-A7
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement (2007), CLSI, Wayne, PA M100-S17
11. Deshpande L.M., Rhomberg P.R., Sader H.S., and Jones R.N. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn. Microbiol. Infect. Dis. 56 (2006) 367-372
12. Felmingham D., White A.R., Jacobs M.R., Appelbaum P.C., Poupard J., Miller L.A., and Gruneberg R.N. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 56 Suppl 2 (2005) ii3-ii21
13. Fridkin S.K., Edwards J.R., Tenover F.C., Gaynes R.P., and McGowan Jr. J.E. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin. Infect. Dis. 33 (2001) 324-330
14. Gales A.C., Biedenbach D.J., Winokur P., Hacek D.M., Pfaller M.A., and Jones R.N. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn. Microbiol. Infect. Dis. 39 (2001) 125-127
15. Harding I., and Felmingham D. PROTEKT years 1-3 (1999-2002): study design and methodology. J. Chemother. 16 Suppl 6 (2004) 9-18
16. Hossain A., Ferraro M.J., Pino R.M., Dew III R.B., Moland E.S., Lockhart T.J., Thomson K.S., Goering R.V., and Hanson N.D. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter spp. Antimicrob. Agents Chemother. 48 (2004) 4438-4440
17. Jones R.N., Deshpande L., Fritsche T.R., and Sader H.S. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). Diagn. Microbiol. Infect. Dis. 49 (2004) 211-216
18. Jones R.N., and Masterton R. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 41 (2001) 171-175
19. Jones R.N., Mendes C., Turner P.J., and Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn. Microbiol. Infect. Dis. 53 (2005) 247-256
20. Landman D., Quale J.M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., Flores C., and Brooks S. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162 (2002) 1515-1520
21. Mammeri H., Van De Loo M., Poirel L., Martinez-Martinez L., and Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob. Agents Chemother. 49 (2005) 71-76
22. Masterton R.G., and Turner P.J. Overview of the Meropenem Yearly Susceptibility Test Information Collection (1997-2004). Diagn. Microbiol. Infect. Dis. 53 (2005) 245-246
23. Naas T., Nordmann P., Vedel G., and Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob. Agents Chemother. 49 (2005) 4423-4424
24. Nordmann P., and Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8 (2002) 321-331
25. Pfaller M.A., and Jones R.N. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. J. Antimicrob. Chemother. 46 Suppl B (2000) 25-37
26. Pfaller M.A., Jones R.N., and Biedenbach D.J. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41 (2001) 177-182
27. Poirel L., Leviandier C., and Nordmann P. Prevalence and genetic analysis of plasmid-mediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French university hospital. Antimicrob. Agents Chemother. 50 (2006) 3992-3997
28. Poirel L., Nguyen T.V., Weintraub A., Leviandier C., and Nordmann P. Plasmid-mediated quinolone resistance determinant qnrS in Enterobacter cloacae. Clin. Microbiol. Infect. 12 (2006) 1021-1023
29. Pottumarthy S., Moland E.S., Juretschko S., Swanzy S.R., Thomson K.S., and Fritsche T.R. NMC-A carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg. Infect. Dis. 9 (2003) 999-1002
30. Rasmussen B.A., Bush K., Keeney D., Yang Y., Hare R., O'Gara C., and Medeiros A.A. Characterization of IMI-1 β-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob. Agents Chemother. 40 (1996) 2080-2086
31. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J. Chemother. 17 (2005) 459-469
32. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagn. Microbiol. Infect. Dis. 54 (2006) 249-257
33. Rhomberg P.R., and Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the United States component (2005). Diagn. Microbiol. Infect. Dis. 57 (2007) 207-215
34. Sader H.S., Fritsche T.R., and Jones R.N. Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn. Microbiol. Infect. Dis. 52 (2005) 265-273
35. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J. Clin. Microbiol. 34 (1996) 2909-2913
36. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., and Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33 (1995) 2233-2239
37. Tenover F.C., Kalsi R.K., Williams P.P., Carey R.B., Stocker S., Lonsway D., Rasheed J.K., Biddle J.W., McGowan Jr. J.E., and Hanna B. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg. Infect. Dis. 12 (2006) 1209-1213
38. Turner P.J. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997-2003). Diagn. Microbiol. Infect. Dis. 50 (2004) 291-293
39. Turner P.J. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study. Diagn. Microbiol. Infect. Dis. 53 (2005) 273-279
40. Walsh T.R., Toleman M.A., Poirel L., and Nordmann P. Metallo-β-lactamases: the quiet before the storm?. Clin. Microbiol. Rev. 18 (2005) 306-325
41. Woodford N., Tierno Jr. P.M., Young K., Tysall L., Palepou M.F., Ward E., Painter R.E., Suber D.F., Shungu D., Silver L.L., Inglima K., Kornblum J., and Livermore D.M. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48 (2004) 4793-4799
42. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., Alberti S., Bush K., and Tenover F.C. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45 (2001) 1151-1161